X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will utilize engineered T-cell therapies targeting MAGE-A4 and mesothelin. These targets are expressed on a broad range of solid tumors and are supported by compelling early- and late-stage clinical data.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Adaptimmune Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 06, 2023
Details:
Gavo-cel (TC-210) demonstrated a disease control rate (DCR) of 77%, which is defined in the Phase 1 portion of the trial as a response or sustained stable disease for at least three months post infusion.
Lead Product(s): Gavocabtagene Autoleucel,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: TC-210
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
The collaboration leverages Arbor’s proprietary CRISPR gene-editing technology and TCR 2’s’ TRuC platform, which has demonstrated clinical activity in multiple treatment-refractory mesothelin-expressing solid tumor indications with its lead autologous program Gavo-cel.
Lead Product(s): Gavocabtagene autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Gavo-cel
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Arbor Biotechnologies, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2022
Details:
Under clinical trial collaboration, Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo® (nivolumab) and Yervoy® (ipilimumab) in its planned Phase 2 clinical trial in treatment refractory mesothelin-expressing solid tumors.
Lead Product(s): Gavocabtagene Autoleucel,Nivolumab
Therapeutic Area: Oncology Product Name: Gavo-cel
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 25, 2021
Details:
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin for mesothelin-expressing solid tumors.
Lead Product(s): Gavocabtagene Autoleucel,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: TC-210
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The strategic partnership will focus on the production of TC-210, TCR2’s TRuC-T cell targeting advanced mesothelin-expressing cancer, to support the anticipated Phase II clinical trial.
Lead Product(s): TC-210,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: TC-210
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: ElevateBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2020
Details:
Company plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in a premarket press release and webcast to be held on Monday, July 27th, 2020.
Lead Product(s): TC-210,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: TC-210
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
Stephen Webster will assist TCR² Therapeutics in advancing their third mono TRuC-T cell therapy towards the clinic.
Lead Product(s): TC-210,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
